Yale School of Medicine, 333 Cedar St, New Haven, CT, USA.
Yale School of Medicine, 333 Cedar St, New Haven, CT, USA; Cancer Outcomes, Public Policy, and Effectiveness Research (COPPER) Center at Yale, 333 Cedar St, New Haven, CT, USA.
J Geriatr Oncol. 2021 Jan;12(1):102-105. doi: 10.1016/j.jgo.2020.05.010. Epub 2020 Jun 10.
Although survival after a cancer diagnosis has improved considerably over the past 20 years, little is known about trends in health-related quality-of-life (HRQOL) for older prostate, breast, and lung cancer survivors.
Using a population-based registry with longitudinal patient reported outcomes (the National Cancer Institute Surveillance, Epidemiology and End Results database linked to Medicare Health Outcomes Survey), we analyzed Medicare Advantage patients diagnosed with cancer during 1998-2011, who completed surveys regarding HRQOL through 2013. 'Early Era' patients were treated during 1998-2003; 'Late Era' patients were treated during 2006-2011. After propensity score matching, post-diagnosis changes in health utility (HU), Physical Component Summary (PCS) and Mental Component Summary (MCS) scores were calculated and compared between the two eras.
We identified 208 older patients with prostate, 276 with breast and 76 with lung cancer who were treated in the 'Early Era' and matched to equal numbers in the 'Late Era'. Mean age of patients in early and late era was 72 and 73 years, respectively. The mean post-diagnosis decline in health utility for patients treated in the 'Late Era' was not significantly different from the 'Early Era' for any cancer (Prostate [early vs. late]: -0.06 vs. -0.03, p = .09; Breast: -0.03 vs. -0.04, p = .65; Lung: -0.07 vs. -0.07, p = .95); nor for Physical Component Summary or Mental Component Summary scores.
Older patients treated for prostate, breast or lung cancer in the later era reported similar outcomes of changes in HRQOL compared to earlier era patients.
尽管在过去 20 年中,癌症诊断后的生存率有了显著提高,但对于老年前列腺癌、乳腺癌和肺癌幸存者的健康相关生活质量(HRQOL)趋势知之甚少。
利用基于人群的登记处和纵向患者报告结局(国家癌症研究所监测、流行病学和最终结果数据库与医疗保险健康结果调查相关联),我们分析了 1998-2011 年间被诊断患有癌症的医疗保险优势患者,并通过 2013 年完成了关于 HRQOL 的调查。“早期时代”患者在 1998-2003 年期间接受治疗;“晚期时代”患者在 2006-2011 年期间接受治疗。在进行倾向评分匹配后,计算并比较了两个时代之间健康效用(HU)、身体成分综合评分(PCS)和心理成分综合评分(MCS)的诊断后变化。
我们确定了 208 名患有前列腺癌的老年患者、276 名患有乳腺癌的患者和 76 名患有肺癌的患者,他们在“早期时代”接受治疗,并与“晚期时代”的同等数量患者相匹配。早期和晚期时代患者的平均年龄分别为 72 岁和 73 岁。在“晚期时代”接受治疗的患者的健康效用在诊断后的下降幅度与“早期时代”相比,在任何癌症中均无显著差异(前列腺[早期与晚期]:-0.06 对-0.03,p=0.09;乳腺癌:-0.03 对-0.04,p=0.65;肺癌:-0.07 对-0.07,p=0.95);身体成分综合评分或心理成分综合评分也如此。
在较晚时期接受前列腺癌、乳腺癌或肺癌治疗的老年患者与早期时代的患者报告的 HRQOL 变化结果相似。